Treatment for cerebral palsy gait impairment
US9307942B2 · kind B2 · utility
0Cited by
4References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 8, 2015 |
| Grant date | Apr 12, 2016 |
| Priority date | — |
| Expiry date | Jul 8, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61B5/4064
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.